OXBRYTA 500 mg, film-coated tablet 90 tablets

Telegram WhatsApp

Link to share

Active ingredients: VOXÉLOTOR

Commercialized according to BDPMDispensing in France: Prescription only

Film-coated tablet90 tabletsorale

No current ANSM shortage notice is included

Package details

Original BDPM fields are shown in French.

Official name: OXBRYTA 500 mg, comprimé pelliculé
Pharmaceutical form: comprimé pelliculé
Route of administration: orale
Presentation description: 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant polypropylène de 90 comprimé(s)
Marketing authorisation holder: PFIZER EUROPE MA EEIG (BELGIQUE)
Reimbursement according to BDPM: —
Approval for use in healthcare institutions: non
Commercialization declaration date: 4 Oct 2024
Prescription and dispensing conditions: Prescription only
List I: prescription-only medicine
Initial prescription by a hospital doctor
Prescribed by specialists only
Original BDPM wording: liste I · prescription initiale hospitalière annuelle · prescription réservée aux médecins compétents en maladie du sang · prescription réservée aux spécialistes et services HEMATOLOGIE · prescription réservée aux spécialistes et services MEDECINE INTERNE · prescription réservée aux spécialistes et services PEDIATRIE · renouvellement non restreint
Enhanced ANSM monitoring: Yes

BDPM identifiers

CIS62137714CIP73024715CIP133400930247150

Composition in BDPM

Composition in BDPM
Component	Amount per unit	Source type
VOXÉLOTORcomprimé	500 mg · un comprimé	SA

Information is based on BDPM data and is for reference only. Consult a doctor before use.

Similar medicines

Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.

The current BDPM data does not list similar medicines for this product.